Karyopharm Therapeutics Inc (NASDAQ:KPTI) Given Consensus Recommendation of “Buy” by Brokerages

Share on StockTwits

Karyopharm Therapeutics Inc (NASDAQ:KPTI) has been given an average rating of “Buy” by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $19.33.

Several research firms have weighed in on KPTI. ValuEngine upgraded shares of Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 5th. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, July 13th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price (up from $29.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. Robert W. Baird reiterated an “outperform” rating and issued a $25.00 target price (up from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. Finally, Wedbush raised their price objective on shares of Karyopharm Therapeutics from $11.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday.

In related news, CEO Michael Kauffman sold 10,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.00, for a total value of $120,000.00. Following the completion of the transaction, the chief executive officer now owns 539,767 shares of the company’s stock, valued at $6,477,204. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sharon Shacham sold 20,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00. Company insiders own 13.26% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in KPTI. Bank of Montreal Can bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $29,000. BNP Paribas Arbitrage SA grew its position in shares of Karyopharm Therapeutics by 169,300.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after acquiring an additional 10,158 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Karyopharm Therapeutics by 12.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after acquiring an additional 1,319 shares during the period. Parametric Portfolio Associates LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $128,000. Finally, Premier Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $160,000. 82.55% of the stock is owned by institutional investors and hedge funds.

KPTI traded down $0.40 during mid-day trading on Friday, hitting $10.92. The stock had a trading volume of 58,397 shares, compared to its average volume of 1,499,003. The stock’s fifty day simple moving average is $9.25 and its 200-day simple moving average is $6.69. The company has a debt-to-equity ratio of 1.46, a current ratio of 6.93 and a quick ratio of 6.93. The firm has a market capitalization of $691.65 million, a price-to-earnings ratio of -3.49 and a beta of 2.41. Karyopharm Therapeutics has a 1-year low of $3.92 and a 1-year high of $19.19.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 6th. The company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.97) by $0.26. The company had revenue of $9.49 million for the quarter. Karyopharm Therapeutics had a negative net margin of 2,138.80% and a negative return on equity of 154.75%. As a group, research analysts expect that Karyopharm Therapeutics will post -3.65 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Featured Article: Debt-To-Equity Ratio

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.